Online inquiry

IVTScrip™ mRNA-Anti-IL15RA, ALT-803(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2193MR)

This product GTTS-WQ2193MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL15RA gene. The antibody can be applied in Bladder Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001243539.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3601
UniProt ID Q13261
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL15RA, ALT-803(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2193MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3482MR IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BA1126
GTTS-WQ14538MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SAR156597
GTTS-WQ1239MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABT-165
GTTS-WQ12851MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OPN-305
GTTS-WQ7308MR IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FPA-144
GTTS-WQ3496MR IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAN-2401
GTTS-WQ6405MR IVTScrip™ mRNA-Anti-PDCD1, CT-011(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CT-011
GTTS-WQ15127MR IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SYD985
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW